Viral Hepatitis

Viral Hepatitis

The Alliance for Public Health is a leading professional organization in Ukraine working to counter the spread of the epidemics of hepatitis C virus (HCV), HIV/AIDS, tuberculosis and other socially dangerous diseases. The Alliance is an implementer of the National HIV/AIDS Program in Ukraine with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria.

A primary areas of Alliance work is fighting the spread of HCV by scaling up access to HCV diagnostics and treatment among key affected groups and the general population.

Starting from 2009, the Alliance has been implementing regular HCV treatment programs among key population members.

In 2012 the Alliance and its partners initiated the national advocacy campaign “Demand Treatment!”, which includes a component of testing among the general population.  The campaign contributed to raising public awareness of routes of transmission and prevention of HCV, mobilizing communities and stakeholders to counter the hepatitis C epidemic; reducing prices of HCV diagnostics and treatment; developing and approving State Targeted Social Programs and 15 regional programs for Viral Hepatitis Prevention, Diagnostics and Treatment; allocating state and local budget funds; registering Sofosbuvir in the State Register of Medical Drugs of Ukraine, and launching the first program of HCV treatment, in particular with new direct-acting antivirals (DAAs).

In 2013 the Alliance started the first program of HCV treatment with peg-interferon and ribavirin in Ukraine.

In 2015, thanks to advocacy to reduce the price of sofosbuvir down to $900, the Alliance in partnership with the Ukrainian Center for Socially Dangerous Disease Control launched an innovative HCV treatment program with DAA. The program is aimed at expanding access to treatment with new modern drugs and stipulates treatment of 1,500 patients, mostly members of key populations, with its further expansion in 2016–2017.  Currently the Alliance aims to scale up its treatment programs and enroll a larger number of patients, including members of key populations, on state and regional hepatitis treatment programs, and initiate treatment with innovative drugs funded by state and regional budgets.

Starting from 2015, the Alliance Centre on HIV, Hepatitis C and Drug Use initiated a global campaign “Unite to Eliminate HepC: Know it, Test it, Treat it”.

The campaign calls on non-governmental and patient organizations, governments, pharma and diagnostic companies, international donors and UN agencies to unite to expand access to treatment and eliminate the HCV epidemic at global level. This campaign united more than 20,000 participants, including international organizations from among Alliance partners, representatives of WHO, GF, UNITAID, and communities at international and national levels.